FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

TATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OWR APPRO	JVAL				
OMB Number:	3235-0287				
Estimated average burd	en				
hours per response:	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* ADAMS ADRIAN				<u>A(</u>	2. Issuer Name and Ticker or Trading Symbol ACELRX PHARMACEUTICALS INC ACRX									5. Relationship of Reporting (Check all applicable) X Director			g Pers	on(s) to Issu 10% Ow		
	`	RMACEUTICA	(Middle) CEUTICALS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 06/25/2019										(give title		Other (s below)	pecify
(Street) REDWO CITY (City)	C		94063 (Zip)		4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Indi Line) X					
		Tab	le I - Nor	n-Deriv	vative	e Se	curitie	s Ac	quir	ed, Di	spo	sed o	f, or Be	nefic	ially	Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				Execution Date,		t, Tr	Transaction Disposed Of (D Code (Instr. 5)				s Acquired (A) or f (D) (Instr. 3, 4 an		5. Amour Securitie Beneficia Owned F	es For ally (D) Following (I) (: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								C	ode V	А	Amount	unt (A) or		ice	Transact (Instr. 3 a	on(s)			msu. 4)	
Common Stock ⁽¹⁾ 06/25/				5/201	/2019			A		3,750 ⁽²⁾ A		\$	0.00	78,750			D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,	4. Transa Code (I 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expira	5. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		E	B. Price of Derivative Gecurity Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerc	isable	Exp Date	expiration Date	Title	Amo or Num of Shar	ber					
Stock Option (Right to Buy)	\$2.19	06/25/2019			A		7,500		07/25/	/2019 ⁽³⁾	06/2	25/2029	Common Stock	7,5	00	\$0.00	7,500		D	

Explanation of Responses:

- $1. \ Each \ restricted \ stock \ unit \ represents \ a \ contingent \ right \ to \ receive \ one \ share \ of \ the \ Issuer's \ common \ stock.$
- 2. The restricted stock units shall vest in two equal consecutive annual installments on June 25, 2020 and June 25, 2021, subject to Reporting Person's continuous service to the Company.
- 3. The shares subject to the option vest as follows: 1/24th of the shares subject to the option vest in equal monthly installments over 24 months, subject to Reporting Person's continuous service to the Company.

Remarks:

/s/ Martha Adler, Attorney-In-

** Signature of Reporting Person

06/25/2019

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.